Bausch: Potential Breakthrough in Depression Treatment to Unlock $3B Opportunity?
Myers Squibb Company, Johnson & Johnson, Bausch Health Companies Inc, AbbVie Inc. Read 's Market Analysis on Investing.com ...
Frontiers26 天
Post-marketing safety surveillance of vortioxetine hydrobromide: a pharmacovigilance study ...
First College of Clinical Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China Background: Vortioxetine hydrobromide is a widely prescribed medication for the ...
psychiatryadvisor.com28 天
Extended Release Bupropion HBr is Promising for Treatment Resistant Depression
Source: Getty Images At the 2024 Neuroscience Education Institute Scientific Congress, researchers Maxwell Price and Richard Price, MD presented on the promising effects of extended-release ...
Frontiers3 年
Psychological and Psychopharmacological Interventions in Psychocardiology
Patients with mental disorders have an increased risk to develop cardiovascular disease (CVD), and CVD are frequently comorbid with especially adjustment, anxiety and depressive disorders. Therefore, ...